Lyka Labs' Q3 FY 2025-26 Quarterly Results
- 30 Jan 2026
Result Summary
- Lyka Labs Ltd reported a 15.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 7.9%.
- Its expenses for the quarter were down by 23.9% QoQ and up 3.3% YoY.
- The net profit decreased 95.3% QoQ and decreased 105.5% YoY.
- The earnings per share (EPS) of Lyka Labs Ltd - at - during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 31.89 | 37.75 | 34.62 | -15.5% | -7.9% |
Total Expenses | 32.05 | 42.14 | 31.04 | -23.9% | 3.3% |
Profit Before Tax | -0.16 | -4.38 | 3.57 | -96.3% | -104.5% |
Tax | -0.01 | -1.17 | 0.87 | -99.1% | -101.1% |
Profit After Tax | -0.15 | -3.22 | 2.71 | -95.3% | -105.5% |
Earnings Per Share | 0.00 | -0.94 | 0.75 | -100.0% | -100.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Lyka Labs Ltd is a company operating within the pharmaceutical sector, known for its specialized focus on manufacturing and distributing pharmaceutical products. The company’s portfolio includes a range of generic drugs and formulations aimed at various therapeutic areas. Lyka Labs Ltd is involved in the research, development, and commercialization of these products, catering to both domestic and international markets. As of the data available up to October 2023, there are no specific recent major developments provided about the company in the context of the financial data analyzed. Therefore, any strategic shifts or updates in product lines remain unspecified based on the current data.
Revenue
The financial data for Q3FY26 indicates that Lyka Labs Ltd reported total income of ₹31.89 crore. This represents a decline from the previous quarter, Q2FY26, where the total income stood at ₹37.75 crore, marking a quarter-over-quarter (QoQ) decrease of 15.5%. Compared to the same quarter in the previous fiscal year, Q3FY25, where total income was ₹34.62 crore, there is a year-over-year (YoY) decline of 7.9%. These figures reflect a downward trend in the revenue stream over both the quarterly and annual periods under review.
Profitability
In terms of profitability, the company reported a negative profit before tax (PBT) of ₹-0.16 crore for Q3FY26. This is an improvement from Q2FY26, where the PBT was ₹-4.38 crore, indicating a QoQ improvement of 96.3%. However, when compared to Q3FY25, where the company had a positive PBT of ₹3.57 crore, there is a YoY decline of 104.5%. The tax expense for Q3FY26 was marginally negative at ₹-0.01 crore, compared to ₹-1.17 crore in Q2FY26 and ₹0.87 crore in Q3FY25. Profit after tax (PAT) for Q3FY26 was a loss of ₹-0.15 crore, an improvement from the loss of ₹-3.22 crore in Q2FY26 by 95.3%, but a decline from the profit of ₹2.71 crore in Q3FY25 by 105.5%. Earnings per share (EPS) remained neutral at ₹0.00 in Q3FY26, compared to a negative ₹-0.94 in Q2FY26, but down from ₹0.75 in Q3FY25, reflecting a 100% YoY decrease.
Operating Metrics
Lyka Labs Ltd's operating expenses for Q3FY26 were ₹32.05 crore, which is a decrease from Q2FY26's total expenses of ₹42.14 crore, showing a QoQ reduction of 23.9%. When compared to Q3FY25, where expenses were ₹31.04 crore, there is a slight YoY increase of 3.3%. The substantial reduction in expenses from the previous quarter indicates a significant operational cost control effort. However, despite this, the company continues to report a negative profit margin for the quarter. The analysis does not provide specific financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio, which would require additional data beyond profit, income, and expense figures. The trends suggest fluctuating operating conditions over the periods analyzed, influenced by both income and expenses.